Page 65 - ARNM-2-3

Advances in Radiotherapy
& Nuclear Medicine NCRT for T3N0M0 ESCC

relatively short. Although post-operative pN0 is accurate, surgery alone from the electronic medical record system
current pretreatment diagnostics struggle to identify pN0 of Sichuan Cancer Hospital. In addition, for patients who
disease. Developing methods to identify patients with pN0 underwent NCRT, pathological assessments of LNs were
disease through pretreatment diagnostics is essential to conducted using their pathology slides.
ensure that patients diagnosed with T3N0M0 receive the
most appropriate treatment. References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics
5. Conclusion 2020: GLOBOCAN estimates of incidence and mortality
This study demonstrated that NCRT + S improves OS worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
in patients with pre-T3N0M0 stage disease compared to 2021;71(3):209-249.
surgery alone, especially in those who achieve pCR after doi: 10.3322/caac.21660
NCRT. Moreover, NCRT + S reduces the local recurrence 2. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles
rate in patients with pre-T3N0M0 ESCC. NCRT + S is of cancer burden worldwide and in China: A secondary
recommended for patients with pre-T3N0M0 who are analysis of the global cancer statistics 2020. Chin Med J
likely to achieve pCR after NCRT. There is a demand for a (Engl). 2021;134(7):783-791.
noninvasive pretreatment method to accurately determine doi: 10.1097/CM9.0000000000001474
patients who are likely to achieve pCR.
3. Eyck BM, Van Lanschot JJ, Hulshof M, et al. Ten-year
Acknowledgments outcome of neoadjuvant chemoradiotherapy plus surgery
for esophageal cancer: The randomized controlled CROSS
We gratefully acknowledge Sichuan Cancer Hospital and trial. J Clin Oncol. 2021;39(18):1995-2004.
Institute for the clinical data supported.
doi: 10.1200/JCO.20.03614
Funding 4. Yang H, Liu H, Chen Y, et al. Neoadjuvant
chemoradiotherapy followed by surgery versus surgery
This work was supported by the Science and Technology alone for locally advanced squamous cell carcinoma of the
Department of Sichuan Province (2023YFS0488 and esophagus (NEOCRTEC5010): A phase III multicenter,
2023YFQ0055), Sichuan. randomized, open-label clinical trial. J Clin Oncol.
2018;36(27):2796-2803.
Conflict of interest
doi: 10.1200/JCO.2018.79.1483
The authors declare no conflicts of interest.
5. Shapiro J, Van Lanschot JJ, Hulshof M, et al. Neoadjuvant
Author contributions chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term
Conceptualization: Qifeng Wang results of a randomised controlled trial. Lancet Oncol.
Investigation: Ying Liu, Yehan Zhou, Xiaoding Zhou, 2015;16(9):1090-1098.
Jingqiu Li, Jie Zhu, Yi Wang, Lei Wu, Gang Wan, doi: 10.1016/S1470-2045(15)00040-6
Xuefeng Leng, Guangyuan Liu, Yongtao Han, Yang 6. Markar SR, Gronnier C, Pasquer A, et al. Role of neoadjuvant
Liu, Lin Peng treatment in clinical T2N0M0 oesophageal cancer: Results
Methodology: Yehan Zhou from a retrospective multi-center European study. Eur J
Writing – original draft: Ying Liu Cancer. 2016;56:59-68.
Writing – review & editing: Yehan Zhou, Qifeng Wang
doi: 10.1016/j.ejca.2015.11.024
Ethics approval and consent to participate 7. Mantziari S, Gronnier C, Renaud F, et al. Survival benefit
Ethical approval permission has been obtained from the of neoadjuvant treatment in clinical T3N0M0 esophageal
cancer: Results from a retrospective multicenter European
Regional Ethical Committee (Nos: SCCHEC‐02‐2023‐029). study. Ann Surg. 2017;266:805-813.
Consent for publication doi: 10.1097/sla.0000000000002402

Not applicable. 8. Rhodin KE, Raman V, Jawitz OK, et al. Patterns of use of
induction therapy for t2n0 esophageal cancer. Ann Thorac
Availability of data Surg. 2021;111(2):440-447.

This study retrospectively collected clinicopathological doi: 10.1016/j.athoracsur.2020.05.089
data of ESCC patients who underwent either NCRT or 9. Goense L, Visser E, Haj Mohammad N, et al. Role of

Volume 2 Issue 3 (2024) 10 doi: 10.36922/arnm.3821